Meeting Banner
Abstract #1366

Distinguishing the Chemical Signature of Different IDH Mutations in Brain Tumor Patients at 7 Tesla

Uzay E Emir1, Sarah Larkin2, Nick de Pennington2, Puneet Plaha3, Natalie Voets1, James Mccullagh4, Richard Stacey3, Peter Jezzard1, Stuart Clare1, Christopher Schofield4, Tom Cadoux-Hudson3, and Olaf Ansorge2

1FMRIB Centre, University of Oxford, Oxford, United Kingdom, 2Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom, 3Department of Neurosurgery, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, 4Department of Chemistry, University of Oxford, Oxford, United Kingdom

In this study, we show a proton magnetic resonance spectroscopy (1H-MRS) acquisition scheme at 7T, enabling discernible 2-HG in the spectra of IDH-mutant patients acquired within 20s and quantify metabolic changes associated with the IDH mutation. Due to the increased sensitivity and specificity of this scheme at 7T, we demonstrate elevated 2-HG and Lactate accumulation in IDH2 R172K (mitochondrial) compared to the IDH1 R132H (cytosolic) mutant tumors in human brains noninvasively.

This abstract and the presentation materials are available to members only; a login is required.

Join Here